Arrow Mark Colorado Holdings LLC Alnylam Pharmaceuticals, Inc. Transaction History

Arrow Mark Colorado Holdings LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$122.97 - $147.0 $188,635 - $225,498	-1,534 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$104.21 - $156.44 $204,981 - $307,717	-1,967 Reduced 56.18%	1,534 $227,000
Q1 2020 May 15, 2020	SELL	$93.12 - $133.99 $100,197 - $144,173	-1,076 Reduced 23.51%	3,501 $381,000
Q3 2019 Nov 14, 2019	SELL	$70.9 - $87.82 $884,477 - $1.1 Million	-12,475 Reduced 73.16%	4,577 $368,000
Q2 2019 Aug 14, 2019	BUY	$65.86 - $92.79 $1,909 - $2,690	29 Added 0.17%	17,052 $1.24 Million
Q1 2019 May 15, 2019	SELL	$72.76 - $93.45 $1.3 Million - $1.67 Million	-17,921 Reduced 51.28%	17,023 $1.59 Million
Q2 2018 Aug 14, 2018	SELL	$88.31 - $107.8 $108,003 - $131,839	-1,223 Reduced 3.38%	34,944 $3.44 Million
Q1 2018 May 15, 2018	SELL	$115.92 - $148.54 $31.6 Million - $40.5 Million	-272,872 Reduced 88.3%	36,167 $4.31 Million
Q4 2017 Feb 14, 2018	SELL	$114.49 - $139.98 $22.3 Million - $27.3 Million	-194,850 Reduced 38.67%	309,039 $39.3 Million
Q3 2017 Nov 14, 2017	BUY	$72.53 - $118.27 $36.5 Million - $59.6 Million	503,889	503,889 $59.2 Million

670

112M

839K

771K

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Arrow Mark Colorado Holdings LLC, based on Form 13F filings with the SEC.

Stay updated on Arrow Mark Colorado Holdings LLC with notifications on news.